Skip to content
EmergingResearch compound

SM‑04554

Experimental hair loss compound applied to the skin; an early human study showed only a modest gain, not approved.

SM-04554 vial

DETAILED OVERVIEW

What is SM-04554?

SM-04554 is an experimental compound applied to the skin, developed for pattern hair loss. It is not approved as a medicine anywhere, is not available as a routine treatment and is used only within clinical studies, and its further development is uncertain.

It tries to switch on a signalling pathway that plays a key role in how hair follicles form and renew, so that in theory new follicles would develop. In an early human study the hair count rose measurably compared with a preparation without the active ingredient, but the improvement was modest and there is no large confirmatory study, so any benefit is unproven. Mild local redness and itching occurred and it was generally well tolerated, but its long-term safety in humans is not fully explored. It should be avoided in pregnancy and breastfeeding because there are no human data.

Developer

Samumed / Biosplice Therapeutics

Status

Phase 2 trial, modest and mixed result; not approved

Mechanism of action

Topical Wnt/β-catenin pathway activator (regenerative, NOT antiandrogen)

Evidence

Limited, mixed; no confirmatory phase 3

Access

Trial only; not available as a routine treatment

Data console

Lab data

Classification-
StructureN/A
Molecular weightN/A
Target area-
Storage2–8°C
Stability~30 days reconstituted

Safety

Side effects, stop signs, contraindications

Side effects · 3

  • Local scalp reaction: phase trials reported mild application-site reactions (redness, itching); generally well tolerated, but the full human safety picture is limited.
  • Limited and mixed efficacy data: the phase 2 trial showed only MODEST, not clearly robust hair-count increases, and the further development status is uncertain; do not expect confirmed efficacy.
  • Modulating the Wnt pathway is a theoretical consideration: the Wnt pathway is active in many tissues; for a local topical agent systemic effect is designed to be minimal, but long-term human safety is not fully characterized.

Contraindications · 3

  • Not approved, investigational: no approved indication or dose; not available as a routine treatment.
  • Pregnancy and breastfeeding: avoid due to lack of human data.
  • Broken, inflamed scalp; known hypersensitivity to the active or the vehicle.

Related Hair & Skin

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about SM‑04554?

Educational hair and skin info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation. Talk to a dermatologist!

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.